Structure Therapeutics (NASDAQ:GPCR) Trading 6.3% Higher - Here's What Happened

Key Points

• Structure Therapeutics shares increased by 6.3%, with the stock last trading at $21.48 following a significant decline in trading volume.
• Multiple analysts have updated their ratings on Structure Therapeutics, with one firm upgrading to a "strong buy" while others adjusted their price targets downward.
• The company reported a quarterly loss of ($0.36) EPS, missing the consensus estimate, and is projected to post -0.82 EPS for the current year.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) shares shot up 6.3% during trading on Tuesday . The stock traded as high as $21.21 and last traded at $21.48. 142,553 shares traded hands during trading, a decline of 84% from the average session volume of 899,567 shares. The stock had previously closed at $20.20.

Analysts Set New Price Targets

Several research firms have commented on GPCR. Guggenheim reduced their price objective on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. JMP Securities cut their price target on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, June 23rd. Lifesci Capital upgraded Structure Therapeutics to a "strong-buy" rating in a report on Monday, September 8th. Finally, HC Wainwright cut their price target on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Trading Up 1.5%

The company has a market cap of $1.36 billion, a price-to-earnings ratio of -22.46 and a beta of -1.88. The stock has a 50-day simple moving average of $19.22 and a 200 day simple moving average of $20.67.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08). As a group, research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC raised its holdings in Structure Therapeutics by 3,326.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company's stock worth $949,000 after purchasing an additional 53,216 shares during the period. GAMMA Investing LLC lifted its holdings in Structure Therapeutics by 663.8% in the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company's stock valued at $152,000 after acquiring an additional 7,627 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Structure Therapeutics in the fourth quarter valued at approximately $304,000. Trexquant Investment LP lifted its holdings in Structure Therapeutics by 127.6% in the first quarter. Trexquant Investment LP now owns 120,340 shares of the company's stock valued at $2,083,000 after acquiring an additional 67,464 shares during the last quarter. Finally, Zimmer Partners LP lifted its holdings in Structure Therapeutics by 77.1% in the first quarter. Zimmer Partners LP now owns 100,776 shares of the company's stock valued at $1,744,000 after acquiring an additional 43,876 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.